Trial Profile

Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PMR-116 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Pimera

Most Recent Events

18 Jun 2025 According to a Pimera Therapeutics media release, the company received a grant award from the Medical Research Future Fund (MRFF) that will enable the expansion of this study
28 Feb 2022 Accrual to date is 15 participants as per Australian New Zealand Clinical Trials Registry record.
02 Feb 2022 according to a Pimera Therapeutics media release, this study is currently in the dose escalation stage of this study being conducted in Australia.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com